WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Tuesday, September 28, 2004

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=AND	
☐	L1	(malari$ or plasmod$ or malaria$).ti,ab,clm.	5325
☐	L2	L1 and (lsu$ or rrna or r-rna or berghei or plastid).ti,ab,clm.	145
☐	L3	L2 and 1147	0
☐	L4	L2 and 1740	0
☐	L5	L2 and biotin$	8
☐	L6	(kara or ting or tham or nelson or tan).in.	45831
☐	L7	L6 and l1	38
☐	L8	(lsu$ or rrna or r-rna or berghei or plastid$)	20133
☐	L9	L8 and l6	112
☐	L10	L9 and l1	5
☐	L11	(malari$ or plasmod$ or malaria$).clm.	1263
☐	L12	L11 and l8.clm.	44
☐	L13	lsu-rrna.clm.	0
☐	L14	lsurrna.clm.	0
☐	L15	lsu.clm. same rrna.clm.	1
☐	L16	lsu.clm. and rrna.clm.	1
☐	L17	lsu.clm.	30
☐	L18	L17 and (rrna or r-rna or ribosom$)	1
☐	L19	large.clm. near2 (subunit or sub-unit).clm.	111
☐	L20	L19 and l11	4

END OF SEARCH HISTORY

WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Tuesday, September 28, 2004

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=AND	
☐	L1	(malari$ or plasmod$ or malaria$).ti,ab,clm.	5325
☐	L2	L1 and (lsu$ or rrna or r-rna or berghei or plastid).ti,ab,clm.	145
☐	L3	L2 and 1147	0
☐	L4	L2 and 1740	0
☐	L5	L2 and biotin$	8
☐	L6	(kara or ting or tham or nelson or tan).in.	45831
☐	L7	L6 and l1	38
☐	L8	(lsu$ or rrna or r-rna or berghei or plastid$)	20133
☐	L9	L8 and l6	112
☐	L10	L9 and l1	5

END OF SEARCH HISTORY

(12) UK Patent Application (19) GB (11) 2 200 642 (13) A

(43) Date of printing by UK Office 10 Aug 1988

(21) Application No 8806391

(22) Date of filing 17 Jul 1987

(30) Priority data
(31) 6983/86 (32) 17 Jul 1986 (33) AU
1046/87 24 Mar 1987

(86) International application data
PCT/AU87/00226 En 17 Jul 1987

(87) International publication data
WO88/00597 En 28 Jan 1988

(71) Applicant
Saramane Pty Ltd

(Incorporated in Australia-Victoria)

c/o The Walter and Eliza Hall Institute of Medical Research, Royal Parade, Parkville, Victoria, Australia

(72) Inventors
Ursula Anna Kate Kara
Deborah Joan Stenzel
Gillian Robin Bushell
Hendrik Mario Geysen
Allan James Saul

(51) INT CL (as given by ISA)
C07K 7/06 A61K 39/015 39/395 C07K 15/12 C12N 5/00 15/00

(52) Domestic classification (Edition J):
C3H 804 819 F2AA F5A
U1S 2419 C3H

(56) Documents cited by ISA
AU A 66877/86 AU A 39959/85
Proceedings of the National Academy of Sciences (USA), Volume 82, August 1985, pages 5121 to 5125
Journal of Immunological Methods, Volume 86, 1986 pages 257 to 264
Chemical Abstracts, Volume 102, No 3, 1985 January page 378 Abstract No. 20993

(58) Field of search by ISA
IPC WPI and WPIL Keyword: Plasmodium falciparum
US USPA, USP77 USP70
Chemical Abstracts Keyword: Plasmodium falciparum
AU: C07K 15/12, 13/00
C07G 7/00
A61K 39/015

(74) Agent and/or Address for Service
Frank B. Dehn & Co
Imperial House, 15-19 Kingsway, London, WC2B 6UZ

(54) Small molecular weight antigen of Plasmodium falciparum

(57) A small molecular weight antigen of the asexual blood stages of *Plasmodium falciparum* which is characterized by: (i) having an apparent molecular weight in the range of approximately 15 kD to 19 kD; (ii) not showing significant glycosylation by galactose or glucosamine labelling, but being acylated by myristic acid; (iii) being associated with the parasitophorous vacuole membrane and with inclusions and vesicles residing within the cytoplasm of the erythrocyte host cell; and (iv) being recognised by monoclonal antibodies against the asexual blood stages of *P. falciparum* which inhibit parasite growth *in vitro;* or an antigenic fragment thereof. A monoclonal antibody specific for this antigen, and a hybrid cell line which produces this antibody is also disclosed.

GB 2 200 642 A

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 4 :
C07K 7/06, 15/12, C12N 5/00
C12N 15/00, A61K 39/015, 39/395

A1

(11) International Publication Number: WO 88/ 00597

(43) International Publication Date: 28 January 1988 (28.01.88)

(21) International Application Number: PCT/AU87/00226

(22) International Filing Date: 17 July 1987 (17.07.87)

(31) Priority Application Numbers: PH 6983
PI 1046

(32) Priority Dates: 17 July 1986 (17.07.86)
24 March 1987 (24.03.87)

(33) Priority Country: AU

(71) Applicant *(for all designated States except US)*: SARAMANE PTY. LTD. [AU/AU]; The Walter and ELiza Hall Institute of Medical Research, Royal Parade, Parkville, VIC 3052 (AU).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)* : KARA, Ursula, Anna, Kate [DE/AU]; 2/11 Munro Street, Kelvin Grove, QLD 4059 (AU). STENZEL, Deborah, Joan [AU/AU]; 3 Tarcoola Avenue, Ferny Hills, QLD 4055 (AU). BUSHELL, Gillian, Robin [AU/AU]; 194 Arthur Terrace, Bardon, QLD 4065 (AU). GEYSEN, Hendrik, Mario [AU/AU]; 10 Janden Close, Knoxfield, VIC 3180 (AU). SAUL, Allan, James [AU/AU]; 14 Dajarra Street, The Gap, QLD 4061 (AU).

(74) Agents: SLATTERY, John, Michael et al.; Davies & Collison, 1 Little Collins Street, Melbourne, VIC 3000 (AU).

(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FR (European patent), GB, GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), US.

Published
With international search report.

(54) Title: SMALL MOLECULAR WEIGHT ANTIGEN OF *PLASMODIUM FALCIPARUM*

(57) Abstract

A small molecular weight antigen of the asexual blood stages of *Plasmodium falciparum* which is characterized by: (i) having an apparent molecular weight in the range of approximately 15 kD to 19 kD; (ii) not showing significant glycosylation by galactose or glucosamine labelling, but being acylated by myristic acid; (iii) being associated with the parasitophorous vacuole membrane and with inclusions and vesicles residing within the cytoplasm of the erythrocyte host cell; and (iv) being recognised by monoclonal antibodies against the asexual blood stages of *P. falciparum* which inhibit parasite growth *in vitro*; or an antigenic fragment thereof. A monoclonal antibody specific for this antigen, and a hybrid cell line which produces this antibody is also disclosed.

US 20040092490A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2004/0092490 A1**

Draper et al. (43) **Pub. Date: May 13, 2004**

(54) **SUBSTITUTED TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF MALARIA**

(76) Inventors: **Michael Draper**, Plaistow, NH (US); **Mark L. Nelson**, Wellesley, MA (US)

Correspondence Address:
LAHIVE & COCKFIELD
28 STATE STREET
BOSTON, MA 02109 (US)

(21) Appl. No.: **10/128,990**

(22) Filed: **Apr. 24, 2002**

Related U.S. Application Data

(60) Provisional application No. 60/286,193, filed on Apr. 24, 2001.

Publication Classification

(51) **Int. Cl.**[7] **A61K 31/65**; A61K 31/473; A61K 31/353; A61K 31/385

(52) **U.S. Cl.** **514/152**; 514/284; 514/434; 514/453

(57) ABSTRACT

This invention provides a method for treating or preventing malaria in a subject. The method includes administering to the subject an effective amount of a substituted tetracycline compound, such that malaria is treated or prevented. In one aspect, the invention relates to pharmaceutical compositions which include an effective amount of a tetracycline compound to treat malaria in a subject and a pharmaceutically acceptable carrier. The substituted tetracycline compounds of the invention can be used to in combination with one or more anti-malarial compounds or can be used to treat or prevent malaria which is resistant to one or more other anti-malarial compounds.

First Hit Fwd Refs Previous Doc Next Doc Go to Doc#

Generate Collection Print

L12: Entry 29 of 44 File: USPT Jul 31, 2001

US-PAT-NO: 6268160
DOCUMENT-IDENTIFIER: US 6268160 B1

TITLE: Method of screening for anti-malarial compounds

DATE-ISSUED: July 31, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Clough; Barbara	London			GB
Preiser; Peter	London			GB
Wilson; Robert John Macleod	London			GB

US-CL-CURRENT: 435/7.8; 435/69.1, 435/7.22, 435/7.93, 435/71.1, 435/947, 436/501, 436/86, 530/350, 530/822

CLAIMS:

We claim:

1. A method for screening a compound for anti-malarial activity with malarial elongation factor-Tu(EF-Tu) protein, which method comprises

(i) contacting the compound with the EF-Tu protein encoded on the 35 kb circular plastid DNA of Plasmodium falciparum; and

(ii) determining whether the compound binds to and inhibits the protein, any such binding and inhibition suggesting that the compound may have anti-malarial malarial activity.

2. The method of claim 1 wherein the EF-Tu protein has a sequence labelled "eftu-pf" in FIG. 2A (SEQ ID NO: 2).

Previous Doc Next Doc Go to Doc#

Generate Collection | Print

Search Results - Record(s) 1 through 5 of 5 returned.

☐ 1. 20040092490. 24 Apr 02. 13 May 04. Substituted tetracycline compounds for the treatment of malaria. Draper, Michael, et al. 514/152; 514/284 514/434 514/453 A61K031/65 A61K031/473 A61K031/353 A61K031/385.

☐ 2. 6143756. 13 May 99; 07 Nov 00. Antimalarial activity of .beta.-carboline alkaloids. Kara; Anna Ursula, et al. 514/281;. A61K031/44.

☐ 3. WO009835057A1. 05 Feb 98. 13 Aug 98. DIAGNOSIS OF PLASMODIUM INFECTION BY ANALYSIS OF EXTRACHROMOSOMAL GENETIC MATERIAL. KARA, ANNA KATE URSULA, et al. C12Q001/68;.

☐ 4. US 6143756A. Composition for treating malaria. ANG, K H, et al. A61K031/44 A61K031/47 A61K031/55.

☐ 5. WO 8606718A. New quinolinyl and naphthridinyl amino:phenol(s) - have antimalarial activity against e.g. Plasmodium vinckei vinckei, P.falciparum and P.berghei. BARLIN, G, et al. A61K031/44 C07D215/46 C07D471/04.

Generate Collection | Print

Terms	Documents
L9 and L1	5

Prev Page Next Page Go to Doc#

WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Wednesday, September 29, 2004

Hide?	Set Name	Query	Hit Count
		DB=USPT; PLUR=YES; OP=AND	
☐	L1	6313090.pn.	1
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR	
☐	L2	(large.clm. near2 (subunit or sub-unit).clm. and (malari$ or plasmod$ or malaria$).clm.)	4

END OF SEARCH HISTORY

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/IB 98/00212

A. CLASSIFICATION OF SUBJECT MATTER

Int Cl[6]: C12Q 1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C12Q 1/68

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
WPAT acd CAS online: Plasmodium and (mitochondria or extrachromosom? or extra()chormosomal or Plastid) DNA sequences 1-12 and Figures 9 and 10: Swiss Prot, Genbank, EMBL, PIR.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	M.J. Gardner et al. "Organisation and expression of small subunit ribosomal RNA genes encoded by a 35-kilobase circular DNA in Plasmodium falciparum." Molecular and Biochemical Parasitology Pages 77-88 Volume 48 1991	
X	Whole document	1-36, 39-59
X	Figure 3 is relevant to Sequence 1	37, 38

[X] Further documents are listed in the continuation of Box C

[ ] See patent family annex

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
31 March 1998

Date of mailing of the international search report
21 APR 1998

Name and mailing address of the ISA/AU
AUSTRALIAN PATENT OFFICE
PO BOX 200
WODEN ACT 2606
AUSTRALIA
Facsimile No.: (02) 6285 3929

Authorized officer
ALBERT S. J. YONG
Telephone No.: (02) 6283 2160

Form PCT/ISA/210 (second sheet) (July 1992) copgid

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/IB 98/00212

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	M.J. Gardner et al. "A circular DNA in malaria parasites encodes an RNA polymerase like that of prokaryotes and chloroplasts." Molecular and Biochemical Parasitology Pages 115-123 Volume 44 1991	
X	Whole document	1-36, 39-59
X	Figure 2 is relevant to Sequence 1.	37, 38
	M.J. Gardner et. al. "Sequence an Organization of large subunit rRNA genes from the extrachromosomal 35 kb circular DNA of the malaria parasite Plasmodium falciparum." Nucleic Acids Research pages 1067-1071 Volume 21 1993	
X	Whole document	1-36, 39-59
X	Figure 3 is relevant to Sequence 1	37, 38
	M. J. Gardner et. al. "Nine duplicated tRNA genes on the plastid-like DNA of the malaria parasite Plasmodium falciparum." Gene pages 307-308 Volume 140 1994 & EMBL Accession No. x 75545 eg bases 653-832	
X	Whole document	1-36, 39-59
X	x75545 is relevant to Sequence 1.	37, 38
	R.J.M. Wilson et. al. "Complete Gene Map of the Plastid-like DNA of the Malaria Parasite Plasmodium falciparum." Journal of Molecular Biology pages 155-172 Volume 261 1996 & EMBL Accession No. x952754 and x95276	
X	Whole Document	1-36, 39-59
X	x95275 & x95276 is relevant to Sequences 1&3.	37, 38
	D.H. Williamson et. al. "The evolutionary origin of the 35 kb circular DNA of Plasmodium falciparum: New evidence supports a possible rhodophyte ancestry"	
X	Whole document	1-36, 39-59
X	Figure 2 is relevant to Sequences 1&2.	37, 38
	M.J. Gardner et. al. "Phylogenetic analysis of the ropB gene from the plastid-like DNA of Plasmoduim falciparum". Molecular and Biochemical Parasitology. pages 221-231 Volume 66 1994	
X	Whole document	1-36, 39-59
X	Figure 2 is relevant to Sequences 1&2.	37, 38

INTERNATIONAL SEARCH REPORT

AUSTRALIAN PATENT OFFICE
SEARCH REPORT

Application No.
IB 98/00212

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	P. Preiser et. al. "tRNA genes transcribed from the plastid-like DNA of Plasmodium falciparum" Nucleic Acids Research pages 4329-4336 Volume 23 1995 & EMBL Accession Nos. X90351 - X90354.	
X	Whole document	1-36, 39-59
X	X90351 - X90354 is relevant to Sequences 2 & 3	37, 38
	A.B. Vaidya et. al. "Sequences similar to genes for two mitochordrial proteins and portions of ribosomal RNA in tandemly arrayed 6-kilobase-pair DNA of a malarial parasite". Molecular and Biochemical Parasitology	
X	Whole Document	1-36, 39-59
X	Figure 1 is relevant to Figures 9&10	37, 38
	J.M. Feagin. "Homologies between the contiguous ad fragmented rRNAs of the two Plasmodium falciparum extrachromosomal DNA's are limited to core sequences". Nucleic Acids Research pages 879-887 Volume 20 1992 & Gen Bank Accession No. M7661	
X	Whole document	1-36, 39-59
X	M76611 is relevant to Figures 9&10	37, 38

```
ID   U79731     standard; genomic DNA; INV; 5849 BP.
XX
AC   U79731;
XX
SV   U79731.1
XX
DT   08-DEC-1997 (Rel. 53, Created)
DT   08-DEC-1997 (Rel. 53, Last updated, Version 1)
XX
DE   Plasmodium berghei extrachromosomal plastid PB-1, ORF470
DE   tRNA-Thr, large subunit ribosomal RNA, tRNA-Met, tRNA-Ar
DE   tRNA-Arg, tRNA-Leu, tRNA-Asn, tRNA-Ala, and small subuni
DE   genes, complete sequences.
XX
KW   .
XX
OS   Plasmodium berghei
OC   Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmod
XX
RN   [1]
RP   1-5849
RX   MEDLINE; 98038979.
RX   PUBMED; 9373142.
RA   Yap M.W., Kara U.A., ten Heggeler-Bordier B., Ting R.C.,
RT   "Partial nucleotide sequence and organisation of extrach
RT   plastid-like DNA in Plasmodium berghei";
RL   Gene 200(1-2):91-98(1997).
XX
RN   [2]
RP   1-5849
RA   Yap M.W.C., Kara U.A.K., Tan T.M.C.;
RT   ;
RL   Submitted (26-NOV-1996) to the EMBL/GenBank/DDBJ databas
RL   Institute of Molecular and Cell Biology, National Univer
RL   10 Kent Ridge Crescent S119260, Singapore
XX
FH   Key             Location/Qualifiers
FH
FT   source          1..5849
FT                   /db_xref="taxon:5821"
FT                   /mol_type="genomic DNA"
FT                   /note="extrachromosomal plastid PB-1"
FT                   /organism="Plasmodium berghei"
FT                   /strain="ANKA"
FT   CDS             complement(<1..711)
FT                   /codon_start=1
FT                   /db_xref="GOA:O44057"
FT                   /db_xref="UniProt/TrEMBL:O44057"
```

```
FT                   /note="ORF470"
FT                   /protein_id="AAB88271.1"
FT                   /translation="MINKLKLKKFLNIYNLNYKYQYNNKI
FT                   NIYLYFFIYKFKIYSLKFLNMFKLPDWSCFECPNISYDNI
FT                   LNINFLDTYFNKKIIPIDVICDSISVLHTTQYFLKKLGII
FT                   GTVVSYKDNFFANINSIIFSEGSFCYVSKYIKCSFNLSTY
FT                   EFAYVGYLEGCTASL"
FT   tRNA            complement(739..809)
FT                   /product="tRNA-Thr"
FT   rRNA            complement(814..3521)
FT                   /product="large subunit ribosomal RNA"
FT   tRNA            complement(3565..3636)
FT                   /product="tRNA-Met"
FT   tRNA            complement(3646..3717)
FT                   /product="tRNA-Arg"
FT   tRNA            3742..3813
FT                   /product="tRNA-Val"
FT   tRNA            3817..3888
FT                   /product="tRNA-Arg"
FT   tRNA            3895..3975
FT                   /product="tRNA-Leu"
FT   tRNA            complement(3996..4058)
FT                   /product="tRNA-Asn"
FT   tRNA            4089..4159
FT                   /product="tRNA-Ala"
FT   rRNA            4208..5648
FT                   /product="small subunit ribosomal RNA"
FT   tRNA            5793..5849
FT                   /product="tRNA-Ile"
XX
SQ   Sequence 5849 BP; 2296 A; 673 C; 557 G; 2323 T; 0 other;
     taatgaagct gtacatcctt ctaaatatcc aacatatgca aattcacttg c
     agtacgttca aattgtgcaa aatcataaga attagtctta aaataagttg a
     actacatttt atatacttag acacataaca aaaagatcct tcactaaaaa t
     aatatttgca aaaaaattat ctttataaga aactacagtt cctaaatatt t
     taaaggatat tttaaaataa cgtccaataa agacaaaaat ataataccta a
     aaaatattgt gttgtatgta aaacagatat actatcacaa ataacatcaa t
     ttttttatta aaataggtat ctaaaaaatt tatatttaaa ttagttttta a
     caaattacta tcttttaaag tagaagaata ataaataata ttatcataac t
     acattcgaaa cacgaccaat ctggtaattt aaacatattt aaaaatttta a
     tttaaatttg taaataaaaa aatataaata aatattatta gataaatttt t
     tttatttaat ccatttctta ttaaatataa atttatttta ttattatatt g
     atttaaatta taaatattta aaaatttttt taattttaat ttatttatca t
     atattataaa atatttcaag ttaacgatga gatttgaact cacaatctac t
     tcagttgctt taccaattaa gccactttaa caaatataat atttataatt a
     cttattagga attatacaca aaatatatta ctataaatac atattaattc t
     tttttctaat tattgtttta ttcatttata tgattagaat attattttta a
     cttatttata ttacttcaac aattaaaatt ttatacttaa ctactcaaca t
     taataattga tatatcattg gtataatttt ttcgatcctc tcgtactaga a
     tcaatattct aacacttata ttagatatgg accgaactgt ctcacgacgt t
     gctcacgtat cgctttaata ggcgaacaga cttaccctta aaacatacta c
     atgcgataag ccgacatcga ggtgccaaac cttttcgtca atatggactc t
     ttagcctgtt atccctagag taacttttat ccgttaagcg ataattttat t
     ttatcggatc attaagaccg acattaatct ctgtttaatt tgtaaatttt a
     atatatttat ctttatataa taaatataac attgtacacc tccgttttta t
     gaccgcccca gtcaaactat cttataaata ttgttaaaaa ttttgttata a
     aagaatttat atatatataa aatggtattt cattaacaat tacattattt c
     aatattacta cttcccattt attctatgtt atatatatat attttcaata t
     gtaaagcttc atagggtctt tctgtcctaa tataagaaat ctgcatcttc a
```

```
ttatttcatt aagatttttt ttaagacagc atttaagtcg ttacatcttt c
ggaacttacc cgacaaggaa tttcgctacc tttggaccgt tatagataca g
actatagctt atatatatat tataatttta aattataaat attattttta c
ctgggcagat gtcaatcttt atacatcatc tttcgattta gcaaagattt g
taaacagtcg cttaaatttt ttgttttcaa ctaaataagt atctcttctc c
acgagataaa tttgccgagt tccttaaaaa aaattatctc aacttcttaa t
atatttacta gtgtcagttt acagtacgaa tacataataa tatatatata t
ttatataata taatatattt attattatat tagttttaaa atataaatat t
tataagaata ttaacttatt acctatcgat tacacattac atctcatctc a
taaccctatt taaaataata ataaatagga gcccttaaat tatagaagta t
accaatattt acattactca aattagcatt atcacttttg atataattat t
catataaata atttatattc aaaacgctct tttaccaatt taattttatt a
tttatacata tcgataatta atttattttc gattatttct gaactaaaat t
atgagctttt acgcactctt taaaagataa ctgcttctaa atttactttt t
aataatttta tattcttttt aagacttaat taatatttaa aaatcttaat t
ggctgtttcc cttttgaaaa taaagcttat cctttatttt ctgatcatat a
ttaaataaaa ttcttaaatt attttcatta atattaacta tataaattaa t
aaagagtttt acatttattt atatataaat actatactta catatatttc a
agctatcttc aaattcgatt ggcatttcac ctctaattat actttatttg a
aacagtaacc aattcaaact tcaatttaat tttatttaaa tcttatttta a
gatcatttga tttcgggtct ataataaata atatactaaa tgcttattat a
aaactcgagt atactttggc ttcatttata aatatttaac ctaataatta t
tataacttgc taattctttc ttcaacaaga aaataataaa attatattaa a
tatttattaa atttaaaatt caggttcttt tcactatttt ctcaaaatcc t
tccctcacgg tactattcac tatcaacttt tattatatta aattttataa g
aattatattt atattattca tataaaatat atttttatat tacttaatta a
tatataatgt tttaaatctt tcagttcgct cgccactact atgaaaatcg t
atattccttt aagtactaag atgattcagt tccttaagtt tttttaaaat a
aaataaattt ttattcagat acttttataa ttttaataat aaaaaatttt a
aatttttttat aattataaaa atttcgttaa tatatttaac gtctttcttc a
ataatagaca tccttttaaa tttattatat atatttaatt atatatttaa c
tataaattaa tttatttaaa ataagcgaaa aacggaattg aaccgattac c
tgaatccgac gaactttcct tatgctctat ttcgctaaat acaattaaac t
ttgaactttt attttataat tcgtacttat atattttatc cattaaatta c
atattataat atataaatta taagtaatta acttagaggt aaagtttctg c
agaagatcat tggttcgatt ccaatattac ttaaataaat ctataattta a
taaaaacctt ctaagtttta tatgtaagtt caaatcttac tagatttaat a
atggcgaaaa ggtaaacgcg ctaaatttag aatttagttt ttataataat a
atctctttat tcatatttat aatatacttc ttaaactagg attgaactag t
ttaacagccg aatgctttaa ccactaagct attaagaata ttaatattat a
atataatagg gaatatagtt taatggtaaa atcttattct tgcataataa a
tcaattctac ttatttccat attataaaat ctataaatgt tataattttt a
tatataatta tattgcgagt ttgatcctag ctcagaatga acgctagaaa t
acatgcaaat ttatggatta tatcatagtg aataggtgag gatatataaa t
taaatagatt ataatatata ataatctata agcgcattta tttatataat t
taaaaattat tattgtttaa aataaaattt atatttgatt aactagttgg t
gcctaccaag gttatgatca aaaattggtt ttaaagaatg tacaatcaca t
aaataaagcc ctaaattttt tttaaatcag cagtgaggaa tattttacaa t
cttgataaag taatatttct taaaggatga cagtatattt ttatattgta a
tttatttta aatattgata aaaataaaac attagtattt gctaatttct g
cagcggtaat acagaaaata ccagcgttat tcactttatt tggcgtaaag c
ttttatatta attttatttt aaaatattta atttaaattt gaataaaaaa t
tataataaga gtattataaa agtattaaga atttttgag aagtagtgaa a
acaaaaaaga ataccaaagg cgaaggcata atactatata ataactgaca c
aaagctaagg tagcaaatag gattagatac cctagtagtc ttagctgtaa a
ttttatattt atatattaat ataaatataa taactaacgt aataaatatt c
agtatattcg caagaacgaa attcaaagga attgacggga gcttatacaa g
atgtggctta attcgatgca acacgataaa ccttaccaaa atttaacaat a
ttaaggaatt aatagtttaa taaaatatat aggtagtgca tggctgtcgt c
```

```
     tgtgaagtat taatttaagt attataacga acgtaaccct tttataaaaa a
     taatatattt attaaatata taaaaaagac tacgtcaagt cattatgctc c
     gggctgctca cgtgttacat aaaatataac aatattttat tatatgaaaa t
     taaatatatt tatagttctg attataaatt gaaactcatt tatatgaaga t
     agtaatcgct aataagaagt atagcggtga ataagttctt aagctttgta c
     gtcacatctg gaaaatatta tattatataa aaattattgt aaaataataa t
     tataatttag atgaagtcgt aacaaggtag ccgtactgga aggtgcggct g
     ataaaatttt ggttgaatta tttatttaaa aataatattt atatataaaa g
     ttatataatt tttatagaca aaaatagcat taatacacat taatgtaaat t
     attattttat atatataaag gtttttagtt taatggtaaa acatactctt g
     agactttagt tcaattctaa aataaccta
//
```

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 6313090 B1

L3: Entry 1 of 2 File: USPT Nov 6, 2001

DOCUMENT-IDENTIFIER: US 6313090 B1
TITLE: Methods for treating parasitic infection using thiopeptides

Detailed Description Text (13):
The thiopeptides of the present invention can be administered to the subject in amounts sufficient to treat the parasitic infection in the subject as desired. Optimal dosages used will vary according to the individual and the particular parasitic infection, on the basis of age, size, weight, condition, etc, as well as the particular treatment effect being induced. One skilled in the art will realize that dosages are best optimized by the practicing physician and methods for determining dosage are described, for example, in Remington's Pharmaceutical Sciences (36).

Detailed Description Text (14):
In a preferred embodiment, the thiopeptide of the present invention can be administered to a human or a non-human animal in a pharmaceutically acceptable carrier in a dosage range of about 50 to 550 mg/kg/day and is preferably administered in a dosage of about 500 mg/kg/day. Treatment can be continued for an indefinite period of time, as indicated by monitoring of the signs, symptoms and clinical parameters associated with the parasitic infection according to protocols standard in the art for monitoring parasitic infections. Examples of the parameters that would be monitored can include, but are not limited to, amount and frequency of diarrheal excretion, oocyst excretion, culture of the parasite in body fluids and tissues, body weight and blood chemistry and urine analysis of hepatobiliary function. Oocyst excretion can be measured by quantitation of acid-fast stained stool specimens, ELISA antigen capture, immunofluorescence assay, DNA amplification, etc., according to protocols well known in the art.

Detailed Description Text (24):
Assay of Growth inhibition. Thiostrepton (1525 u/mg; Calbiochem) and anisomycin (Sigma) were dissolved at 100 mM in DMSO (Pierce). P. falciparum (strain 3D7) (44) was maintained in culture with human erythrocytes (5% hematocrit) in RPMI-1640 (Life Technologies) supplemented with HEPES and sodium bicarbonate and human sera (10%) under standard conditions (18,19). The growth inhibition assay was conducted as described (20). Briefly, the parasitemia was adjusted to 0.1% parasitemia, 2.5% hematocrit and 200 .mu.l aliquots placed in wells of a microtitre dish. Serial dilutions of drugs were made in RPMI. Thiostrepton was diluted to 10 mM in DMSO before the serial dilutions in RPMI. Aliquots (20 .mu.l) were added in triplicate to the cultures in the microtitre plate, mixing well. At the highest concentrations (final 0.2mM), thiostrepton precipitates. After incubation for 48 hours under standard conditions, [2,8-.sup.3 H]-hypoxanthine Moravek Biochemicals, 12.5